Symbiomix Therapeutics Company

Symbiomix Therapeutics is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecologic infections that can have serious health consequences. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs.On September 18th, 2017, Symbiomix Therapeutics announced that the U.S. Food and Drug Administration (FDA) had approved its lead product Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec™ has been designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration (FDA) for the treatment of BV. QIDP designation creates incentives for the development of new drugs intended to treat serious or life-threatening infections and makes Solosec™ eligible for certain benefits including at least 10 years of market exclusivity. Investors: F-Prime Capital Partners, HBM Partners, Square 1 Bank, OrbiMed.
Technology: Longevity FemTech
Industry: Biopharma, Medical, Pharmaceutical
Headquarters: Newark, Texas, United States
Founded Date: 2012
Employees Number: 11-50
Funding Status: M&A
Investors Number: 5
Total Funding: $47M
Estimated Revenue: $10M to $50M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership